This clinical trial is focused on studying a skin condition called radiation-induced dermatitis, which can occur in patients receiving radiation therapy for breast cancer. The study is testing a new treatment called GR1014 Cutaneous Gel, which contains an active ingredient known as amifostine thiol. This gel is applied to the skin and is being investigated for its ability to protect the skin from damage caused by radiation therapy. The trial will compare the effects of the GR1014 gel with a placebo gel that looks the same but does not contain the active ingredient.

The purpose of the study is to evaluate the safety, tolerability, and effectiveness of the GR1014 gel in preventing skin damage during radiation therapy for patients who have undergone surgery for localized breast cancer. Participants in the study will be randomly assigned to receive either the GR1014 gel or the placebo gel. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment until the study is completed. This helps ensure that the results are not biased.

Throughout the study, participants will apply the gel to the skin area that will receive radiation treatment. The study will monitor the participants from the start of their radiation therapy until four weeks after the last session. Researchers will assess the condition of the skin and any side effects experienced by the participants. The goal is to determine if the GR1014 gel can effectively prevent or reduce the severity of radiation-induced dermatitis compared to the placebo. Participants will be closely monitored by medical professionals throughout the study to ensure their safety and well-being.